Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Short Interest Up 81.0% in January

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 192,015 shares, an increase of 81.0% from the December 31st total of 106,098 shares. Based on an average trading volume of 194,094 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.4% of the shares of the stock are sold short. Currently, 1.4% of the shares of the stock are sold short. Based on an average trading volume of 194,094 shares, the days-to-cover ratio is currently 1.0 days.

Kairos Pharma Price Performance

Shares of NYSEAMERICAN:KAPA traded down $0.00 during trading hours on Friday, hitting $0.66. The company’s stock had a trading volume of 126,041 shares, compared to its average volume of 181,725. The firm’s fifty day moving average price is $0.79 and its 200 day moving average price is $1.02. Kairos Pharma has a 52 week low of $0.40 and a 52 week high of $2.11. The company has a market capitalization of $13.83 million, a price-to-earnings ratio of -2.14 and a beta of 2.28.

Kairos Pharma (NYSEAMERICAN:KAPA) last posted its earnings results on Friday, November 14th. The company reported ($0.07) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, D. Boral Capital reiterated a “buy” rating and set a $9.00 price objective on shares of Kairos Pharma in a research report on Wednesday, November 19th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $8.33.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. FNY Investment Advisers LLC purchased a new stake in Kairos Pharma during the third quarter worth $27,000. XTX Topco Ltd purchased a new stake in shares of Kairos Pharma during the 2nd quarter worth about $44,000. Finally, Two Sigma Investments LP acquired a new stake in shares of Kairos Pharma during the 3rd quarter valued at about $54,000.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.